Human TLR3 Reporter HEK293 Cells (NF-κB and IL-8)

HEK-Blue-Lucia™ hTLR3 Unit size Cat. code Docs Qty Price
Human TLR3 expressing HEK293 dual reporter cells (NF-κB pathway)
3-7 x 10e6 cells

You may also need : Double NF-κB–Readout HEK293 Reporter Cells | View more associated products

Notification: This cell line has been renamed. It was formerly known as "HEK-Dual™ hTLR3 (NF/IL8)". The cat. code (hkd-htlr3ni) remains unchanged.
InvivoGen's cell lines are for internal research use only. Additional rights may be available. Please visit InvivoGen’s Terms and Conditions.

NF-κB–SEAP and IL-8–Lucia reporter HEK293 cells expressing human TLR3

Signaling pathways in HEK-Blue-Lucia™ hTLR3 cells
Signaling pathways in HEK-Blue-Lucia™ hTLR3 cells

HEK-Blue-Lucia™ hTLR3 cells* were engineered from the human embryonic kidney 293 (HEK293)-derived cell line, specifically designed to assess the distinct role of the human Toll-like receptor 3 (hTLR3). Upon recognition of viral or synthetic dsRNA, TLR3 mediates the transcriptional induction of type I interferons (IFNs), proinflammatory cytokines, and chemokines, thereby collectively establishing an antiviral host response [1]. 

More details More details



HEK-Blue-Lucia™ hTLR3 cells were generated from the HEK-Blue-Lucia™ Null​ cell line harboring two inducible reporter genes. This feature allows the double readout of the NF-κB/AP-1 pathway, by monitoring the SEAP (secreted embryonic alkaline phosphatase) or Lucia luciferase activities. These cells stably express the human TLR3 gene. Moreover, they are unresponsive to TLR5 and TNFR stimulation.

Stimulation of HEK-Blue-Lucia™ hTLR3 cells with TLR3 agonists (e.g. Poly(I:C)) triggers the activation of the artificial NF-κB-inducible promoter and the subsequent production of SEAP. It also promotes the expression of Lucia luciferase, which is knocked in (KI) downstream of the endogenous (more physiological) IL-8 promoter (see figures).

IL-8 (interleukin 8) is a chemokine produced in response to TLR agonists in an NF-κB/AP-1-dependent manner [2-3]. This feature enables the double readout study of the NF-κB/AP-1 pathway, by monitoring the activity of SEAP and Lucia luciferase using QUANTI-Blue™ Solution (SEAP detection reagent) or QUANTI-Luc™ 4 Lucia/Gaussia (luciferase detection reagent), respectively. Thus, you may choose the readout depending on your laboratory equipment utilizing a spectrophotometer for SEAP or a luminometer for Lucia luciferase detection.


Key features:

  • Stable expression of human TLR3
  • Strong response to dsRNA and analogs
  • Unresponsive to TLR5 and TNFR stimulation
  • Readily assessable NF-κB activation by assessing the SEAP and/or Lucia luciferase activities


  • Defining the role of TLR3-dependent NF-κB signaling pathway
  • Screening for novel TLR3 agonists and inhibitors
  • Choice of readout depending on the laboratory equipment (spectrophotometer for SEAP or luminometer for Lucia luciferase detection).


* formerly named HEK-Dual™ hTLR3 (NF/IL8) cells



1. Chen Y, et al., 2021.  Toll-like receptor 3 (TLR3) regulation mechanisms and roles in antiviral innate immune responses. J Zhejiang Univ Sci B.;22(8):609-632. 
2. Roebuck KA. 1999. Regulation of interleukin-8 gene expression. J Interferon Cytokine Res:429-38.
3. Ohta K, et al. 2014. Toll-like receptor (TLR) expression and TLR‑mediated interleukin-8 production by human submandibular gland epithelial cells. Mol Med Rep. (5):2377-82.


Response of HEK-Blue™-derived cells (NF-κB - SEAP)
Response of HEK-Blue™-derived cells (NF-κB - SEAP)

Response of HEK-Blue™-derived cells (NF-κB - SEAP). HEK-Blue-Lucia™ hTLR3 (NF/IL8) and HEK-Blue™ hTLR3 cells were stimulated with various TLR ligands and cytokines: TNF-α (10 ng/ml), Poly(I:C) HMW (TLR3 agonist; 100 ng/ml), Poly(I:C) LMW (TLR3 agonist; 100 ng/ml), Poly(A:U) (TLR3 agonist; 100 ng/ml), and FLA‑ST (flagellin from S. typhimurium, TLR5 agonist; 100 ng/ml). After 24h incubation, the NF‑κB‑induced SEAP activity was assessed using QUANTI‑Blue™ Solution and reading the optical density (OD) at 650 nm.

Response of HEK-Blue™-derived cells (IL-8 - Lucia)
Response of HEK-Blue™-derived cells (IL-8 - Lucia)

Response of HEK-Blue™-derived cells (IL-8 - Lucia). HEK-Blue-Lucia™ hTLR3 (NF/IL8) cells were stimulated with TLR3 agonists: Poly(I:C) HMW (100 ng/ml), Poly(I:C) LMW (100 ng/ml) and Poly(A:U) (100 ng/ml). After 24 h incubation, activation of the IL-8 promoter was determined by measuring the relative light units (RLUs) in a luminometer using QUANTI-Luc™ 4 Lucia/Gaussia, a Lucia and Gaussia luciferase detection reagent. Data are shown in fold response over non-induced cells (mean ± SEM).

Back to the top


Antibiotic resistance: BlasticidinHygromycinZeocin®

Growth medium: DMEM, 4.5 g/l glucose, 2 mM L-glutamine, 10% (v/v) heat-inactivated fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin, 100 μg/ml Normocin™

Quality Control:

  • Human TLR3 overexpression has been verified by RT-qPCR and functional assays.
  • The double KO of TLR5 and TNFR has been verified by DNA sequencing, PCR, and functional assays.
  • The stability for 20 passages, following thawing, has been verified.
  • These cells are guaranteed mycoplasma-free. 

Note: HEK-Blue-Lucia™ hTLR3 cells are resistant to BlasticidinHygromycin, and Zeocin®. They should be maintained in growth medium supplemented with Hygromycin and Zeocin®.


These cells are covered by a Limited Use License (See Terms and Conditions).

Back to the top


Dry Ice Shipped on dry ice (Europe, USA, Canada, and some areas in Asia)

Back to the top


In humans, four Toll-Like Receptor (TLR) family members TLR3, TLR7, TLR8, and TLR9 are specialized in sensing viral-derived components and are mainly found in the endosome. Among these, TLR3 recognizes double-stranded (ds)RNA, a hallmark of viral replication, and triggers antiviral immune responses [1]. TLR3 is expressed in myeloid dendritic cells, macrophages, as well as non-immune cells [2].

TLR3 activation upon viral infection involves several steps, including translocation of TLR3 from the ER (endoplasmic reticulum) via the Golgi to the endosome, proteolytic cleavage and dimerization of TLR3, and finally receptor-ligand binding [3]. In order to start the signaling cascade, activated TLR3 recruits the adaptor protein TRIF (TIR domain-containing adapter-inducing interferon-β). TRIF binds to TRAF3 (TNF receptor-associated factor 3), which then recruits TBK1 (TANK-binding kinase 1) and IKKε (IκB kinase ε), thus activating the transcription factor IRF3 (interferon regulatory factor 3) and stimulating the production of type I IFNs (interferons). Additionally, TRIF interacts with TRAF6 and RIP1 (kinase receptor-interacting protein 1). RIP1 in turn binds to TAK1 (transforming growth factor β-activated kinase 1) and IKK. TAK1 phosphorylates IKKα and IKKβ, leading to the phosphorylation of IκB, the NF-κB inhibitor. Ultimately, this leads to the release and translocation of NF-κB into the nucleus and the induction of pro-inflammatory cytokines [2,4]. 

Given its important role in dsRNA recognition, TLR3 signaling has been intensively studied. Various TLR3-agonists, such as the synthetic dsRNA analog Poly(I:C) are being used in vaccine development and cancer therapy [4]. Yet, recent studies have indicated that TLR3 may act as a double-edged sword by showing both protective and damaging functions in the context of some human viral infections [3,5]. Moreover, rare mutations in TLR3 have been associated with viral susceptibility; specifically, infections with HSV-1 (herpes simplex virus 1), influenza, and SARS-Co-V2 have been linked to pathogenic germline variants in TLR3 pathway genes [2]. Understanding the TRIF-dependent TLR3 pathway may be essential for the establishment of specific therapeutic approaches to diminish TLR3-driven disease and exploit its protective functions [3].




1. Manuela Sironi, et al., 2012. A Common Polymorphism in TLR3 Confers Natural Resistance to HIV-1 Infection. J Immunol 15; 188 (2): 818–823. 
2. Aluri, J, et al., 2021. Toll-Like Receptor Signaling in the Establishment and Function of the Immune System. Cells, 10, 1374.
3. Chen Y, et al., 2021.  Toll-like receptor 3 (TLR3) regulation mechanisms and roles in antiviral innate immune responses. J Zhejiang Univ Sci B.;22(8):609-632.
4. Komal A, et al., 2021. TLR3 agonists: RGC100, ARNAX, and poly-IC: a comparative review. Immunol Res. 69(4):312-322. 
5. Perales-Linares R, Navas-Martin S. 2013. Toll-like receptor 3 in viral pathogenesis: friend or foe? Immunology.;140(2):153-67.

Back to the top

FAQ Cell Lines

Visit our FAQ Any questions about our cell lines ? Visit our frequently asked questions page

Back to the top
Customer Service
& Technical Support
Shopping cart is empty